Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

May 18, 2023

Study Completion Date

December 31, 2025

Conditions

Tuberculosis

Interventions

DRUG

BCG-PPD

BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)

Trial Locations (1)

The Third People's Hospital Of Shenzhen, Shenzhen

All Listed Sponsors

collaborator

Shenzhen Third People's Hospital

OTHER

collaborator

Beijing Kangterike Statistical Technology Co., Ltd.

UNKNOWN

collaborator

Wuhan Pulmonary Hospital

OTHER

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT04538911 - Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients | Biotech Hunter | Biotech Hunter